M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
New AMF Series combines industry-leading 1000:1 turndown capability, predictive diagnostics, and digital connectivity in a footprint no larger than a standard Post-it Note pad
The expansion adds 100 m³ of reactor capacity, significantly strengthening Siegfried’s position among the world’s leading CDMOs for small-molecule drug substances
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
AI-powered remote patient monitoring platform earns recognition at AI in Healthcare 2.0 for advancing continuous, preventive, and personalized healthcare delivery
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
